Login / Signup

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis.

Faping WangXiaoju TangMin ZhuHui MaoHuajing WanFeng-Ming Luo
Published in: Journal of clinical medicine (2022)
JAKinibs were superior to placebo for improving signs, symptoms, and health-related quality of life in RA patients at short term, whereas the overall risk of adverse events and infections were greater with baricitinib and upadacitinib, and a higher risk of herpes zoster was only associated with baricitinib. More trials are needed to investigate the long-term safety.
Keyphrases